These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 36711642)

  • 1. Reduced hepatocyte mitophagy is an early feature of NAFLD pathogenesis and hastens the onset of steatosis, inflammation and fibrosis.
    Undamatla R; Fagunloye OG; Chen J; Edmunds LR; Murali A; Mills A; Xie B; Pangburn MM; Sipula I; Gibson G; Croix CS; Jurczak MJ
    Res Sq; 2023 Jan; ():. PubMed ID: 36711642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduced mitophagy is an early feature of NAFLD and liver-specific PARKIN knockout hastens the onset of steatosis, inflammation and fibrosis.
    Undamatla R; Fagunloye OG; Chen J; Edmunds LR; Murali A; Mills A; Xie B; Pangburn MM; Sipula I; Gibson G; St Croix C; Jurczak MJ
    Sci Rep; 2023 May; 13(1):7575. PubMed ID: 37165006
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ALCAT1 controls mitochondrial etiology of fatty liver diseases, linking defective mitophagy to steatosis.
    Wang L; Liu X; Nie J; Zhang J; Kimball SR; Zhang H; Zhang WJ; Jefferson LS; Cheng Z; Ji Q; Shi Y
    Hepatology; 2015 Feb; 61(2):486-96. PubMed ID: 25203315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The protective effect of selenoprotein M on non-alcoholic fatty liver disease: the role of the AMPKα1-MFN2 pathway and Parkin mitophagy.
    Cai J; Huang J; Yang J; Chen X; Zhang H; Zhu Y; Liu Q; Zhang Z
    Cell Mol Life Sci; 2022 Jun; 79(7):354. PubMed ID: 35678878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mitochondrial Dysfunction Plays Central Role in Nonalcoholic Fatty Liver Disease.
    Ramanathan R; Ali AH; Ibdah JA
    Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35806284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mst1 inhibition attenuates non-alcoholic fatty liver disease via reversing Parkin-related mitophagy.
    Zhou T; Chang L; Luo Y; Zhou Y; Zhang J
    Redox Biol; 2019 Feb; 21():101120. PubMed ID: 30708325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A TNFα/Miz1-positive feedback loop inhibits mitophagy in hepatocytes and propagates non-alcoholic steatohepatitis.
    Jin K; Shi Y; Zhang H; Zhangyuan G; Wang F; Li S; Chen C; Zhang J; Wang H; Zhang W; Sun B
    J Hepatol; 2023 Aug; 79(2):403-416. PubMed ID: 37040844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Non-Invasive Assessment of Circulating D-Loop and mt-ccf Levels Opens an Intriguing Spyhole into Novel Approaches for the Tricky Diagnosis of NASH.
    Paolini E; Longo M; Corsini A; Dongiovanni P
    Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of melatonin on fatty liver disease: The role of NR4A1/DNA-PKcs/p53 pathway, mitochondrial fission, and mitophagy.
    Zhou H; Du W; Li Y; Shi C; Hu N; Ma S; Wang W; Ren J
    J Pineal Res; 2018 Jan; 64(1):. PubMed ID: 28981157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatic Mitochondrial Defects in a Nonalcoholic Fatty Liver Disease Mouse Model Are Associated with Increased Degradation of Oxidative Phosphorylation Subunits.
    Lee K; Haddad A; Osme A; Kim C; Borzou A; Ilchenko S; Allende D; Dasarathy S; McCullough A; Sadygov RG; Kasumov T
    Mol Cell Proteomics; 2018 Dec; 17(12):2371-2386. PubMed ID: 30171159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease.
    McGlinchey AJ; Govaere O; Geng D; Ratziu V; Allison M; Bousier J; Petta S; de Oliviera C; Bugianesi E; Schattenberg JM; Daly AK; Hyötyläinen T; Anstee QM; Orešič M
    JHEP Rep; 2022 May; 4(5):100477. PubMed ID: 35434590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IMPACT OF TYPE 2 DIABETES ON NONALCOHOLIC STEATOHEPATITIS AND ADVANCED FIBROSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE.
    Bian H; Zhu X; Xia M; Yan H; Chang X; Hu X; Pan B; Guo W; Li X; Gao X
    Endocr Pract; 2020 Apr; 26(4):444-453. PubMed ID: 31968197
    [No Abstract]   [Full Text] [Related]  

  • 13. NAFLD as a Sexual Dimorphic Disease: Role of Gender and Reproductive Status in the Development and Progression of Nonalcoholic Fatty Liver Disease and Inherent Cardiovascular Risk.
    Ballestri S; Nascimbeni F; Baldelli E; Marrazzo A; Romagnoli D; Lonardo A
    Adv Ther; 2017 Jun; 34(6):1291-1326. PubMed ID: 28526997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. eNOS deletion impairs mitochondrial quality control and exacerbates Western diet-induced NASH.
    Sheldon RD; Meers GM; Morris EM; Linden MA; Cunningham RP; Ibdah JA; Thyfault JP; Laughlin MH; Rector RS
    Am J Physiol Endocrinol Metab; 2019 Oct; 317(4):E605-E616. PubMed ID: 31361543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. From Non-Alcoholic Fatty Liver to Hepatocellular Carcinoma: A Story of (Mal)Adapted Mitochondria.
    Amorim R; Magalhães CC; Borges F; Oliveira PJ; Teixeira J
    Biology (Basel); 2023 Apr; 12(4):. PubMed ID: 37106795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular Mechanisms of Nonalcoholic Fatty Liver Disease (NAFLD)/Nonalcoholic Steatohepatitis (NASH).
    Ota T
    Adv Exp Med Biol; 2021; 1261():223-229. PubMed ID: 33783745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adipose Tissue Insulin Resistance Predicts the Severity of Liver Fibrosis in Patients With Type 2 Diabetes and NAFLD.
    Kalavalapalli S; Leiva EG; Lomonaco R; Chi X; Shrestha S; Dillard R; Budd J; Romero JP; Li C; Bril F; Samraj G; Pennington J; Townsend P; Orlando F; Shetty S; Mansour L; Silva-Sombra LR; Bedossa P; Malaty J; Barb D; Gurka MJ; Cusi K
    J Clin Endocrinol Metab; 2023 Apr; 108(5):1192-1201. PubMed ID: 36378995
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of mitochondrial quality control in the pathogenesis of nonalcoholic fatty liver disease.
    Li R; Toan S; Zhou H
    Aging (Albany NY); 2020 Mar; 12(7):6467-6485. PubMed ID: 32213662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Perilipin-2 promotes obesity and progressive fatty liver disease in mice through mechanistically distinct hepatocyte and extra-hepatocyte actions.
    Orlicky DJ; Libby AE; Bales ES; McMahan RH; Monks J; La Rosa FG; McManaman JL
    J Physiol; 2019 Mar; 597(6):1565-1584. PubMed ID: 30536914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatocyte-specific activity of TSC22D4 triggers progressive NAFLD by impairing mitochondrial function.
    Wolff G; Sakurai M; Mhamane A; Troullinaki M; Maida A; Deligiannis IK; Yin K; Weber P; Morgenstern J; Wieder A; Kwon Y; Sekar R; Zeigerer A; Roden M; Blüher M; Volk N; Poth T; Hackert T; Wiedmann L; De Angelis Rigotti F; Rodriguez-Vita J; Fischer A; Mukthavaram R; Limphong P; Tachikawa K; Karmali P; Payne J; Chivukula P; Ekim-Üstünel B; Martinez-Jimenez CP; Szendrödi J; Nawroth P; Herzig S
    Mol Metab; 2022 Jun; 60():101487. PubMed ID: 35378329
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.